Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Sherron, Kell"'
Autor:
Sherron Kell, Suneel K. Gupta, Robert Rubens, Sarita Khanna, Peter A. LeWitt, Leo Verhagen Metman
Publikováno v:
Clinical Neuropharmacology
Objectives Extended-release (ER) carbidopa-levodopa (CD-LD) (IPX066/RYTARY/NUMIENT) produces improvements in "off" time, "on" time without troublesome dyskinesia, and Unified Parkinson Disease Rating Scale scores compared with immediate-release (IR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff364faed6be393d46b65acc1681b3d
https://doi.org/10.1097/wnf.0000000000000269
https://doi.org/10.1097/wnf.0000000000000269
Autor:
David L. Kreitzman, Robert Rubens, Anette Nieves, Ann Hsu, Robert A. Hauser, James W. Tetrud, Aaron Ellenbogen, Sherron Kell, Grace S. Liang, Sarita Khanna, Eric S. Farbman, Paul A. Nausieda, Suneel K. Gupta, Andrew P. Duker
Publikováno v:
Journal of the Neurological Sciences. 373:116-123
Background IPX066 (Rytary®; carbidopa and levodopa [CD-LD] extended-release capsules) was designed to achieve therapeutic LD plasma concentrations within 1 h of dosing and maintain LD concentrations for a prolonged duration in early or advanced Park
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99b9062bae32711c4cd4429da6a3baed
https://doi.org/10.1016/j.jns.2016.11.047
https://doi.org/10.1016/j.jns.2016.11.047
Autor:
Ramon Gil, Ann Hsu, Nishit B. Modi, Sarita Khanna, Carlos Singer, J Spiegel, Lawrence Elmer, Paul A. Nausieda, Robert Rubens, Suneel K. Gupta, Sherron Kell
Publikováno v:
Journal of Parkinson's Disease
Background Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cae7ac9ab619a0c32a75badec1606df6
https://doi.org/10.3233/jpd-150622
https://doi.org/10.3233/jpd-150622
Autor:
Monika Rudzińska, Ann Hsu, Paul A. Nausieda, Elena S. Tsurkalenko, Sherron Kell, Suneel K. Gupta, Sarita Khanna, Cheryl Waters, J Spiegel, Lyudmila Dzyak, Dee E. Silver
Publikováno v:
CNS Drugs
Background and Objective IPX066 is a multiparticulate extended-release formulation of carbidopa–levodopa, designed to produce prolonged therapeutic levodopa plasma concentrations. This 9-month open-label extension study assessed its long-term safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ff87b81e8b7f10003b8ec70e52edba
http://europepmc.org/articles/PMC4555339
http://europepmc.org/articles/PMC4555339
Introduction: Carbidopa-levodopa extended-release capsules (ER CD-LD, IPX066) significantly improve motor symptoms and activities of daily living in early and advanced Parkinson’s disease (PD). ER CD-LD produces an initial peak in plasma levodopa c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8c8f34f1eb875896add2036504437d
https://europepmc.org/articles/PMC6184647/
https://europepmc.org/articles/PMC6184647/
Autor:
Rajesh, Pahwa, Kelly E, Lyons, Robert A, Hauser, Stanley, Fahn, Joseph, Jankovic, Emmanuelle, Pourcher, Ann, Hsu, Martin, O'Connell, Sherron, Kell, Suneel, Gupta, Olena, Statinova
Publikováno v:
Parkinsonism & Related Disorders. 20(2):142-148
ObjectiveIPX066 is an extended release carbidopa/levodopa formulation designed to rapidly attain and maintain therapeutic plasma concentrations for a prolonged duration, allowing dosing intervals of approximately 6 h. The objective was to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda5b507056dd2acebfa9ca579ba2dd2
Publikováno v:
Innovation in Aging. 1:867-868
Introduction: Carbidopa-levodopa extended-release capsules (ER CD-LD, IPX066) significantly improves motor symptoms and activities of daily living in early and advanced Parkinson’s disease (PD). ER CD-LD produces an initial peak in plasma levodopa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a44ec238ed498062c24fc8f6f15aee9
https://doi.org/10.1093/geroni/igx004.3119
https://doi.org/10.1093/geroni/igx004.3119
Autor:
Suneel K. Gupta, Nishit B. Modi, Sherron Kell, Martin O'Connell, Ann Hsu, Hsuan‐Ming Yao, Leo Verhagen Metman, Aaron Ellenbogen, Robert A. Hauser
Publikováno v:
Movement Disorders. 26:2246-2252
The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended-release formulation of carbidopa-levodopa, with an immediate-release carbidopa-levodopa formulation in advanced Parkinson's disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::289a7c6660fef28f41fe2153b549e388
https://doi.org/10.1002/mds.23861
https://doi.org/10.1002/mds.23861
Autor:
Gilbert Y. Wong, Lars Arendt-Nielsen, Asbjørn Mohr Drewes, Frédérique Menzaghi, Sherron Kell, Anne Estrup Olesen, Camilla Staahl
Publikováno v:
Anesthesiology. 111:616-624
Background Peripherally selective opioids may be beneficial in visceral pain management due to absence of centrally mediated side effects. The objectives of this study were: (1) to assess the effects of a peripherally selective tetrapeptide kappa-opi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0aa6d3b619f06375c5c051630195135
https://doi.org/10.1097/aln.0b013e3181af6356
https://doi.org/10.1097/aln.0b013e3181af6356
Autor:
Scott MacDiarmid, Roger P. Goldberg, Sherron Kell, James H. Barada, Scott Serels, Rodney U. Anderson
Publikováno v:
International Urogynecology Journal. 17:502-511
The efficacy and the tolerability of extended-release oxybutynin chloride, 10 mg daily, and extended-release tolterodine tartrate, 4 mg daily, in women with or without prior anticholinergic treatment for overactive bladder (OAB) were compared in a po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a82339d655d23221c2ee81df3056a87c
https://doi.org/10.1007/s00192-005-0057-7
https://doi.org/10.1007/s00192-005-0057-7